These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37307267)

  • 1. Efficacy, safety and clinical outcome associated with statin use for primary prevention in Korean patients with low-density lipoprotein cholesterol level ≥ 190 mg/dL: A retrospective cohort study.
    Kim HL; Lim WH; Seo JB; Zo JH; Kim MA; Kim SH
    PLoS One; 2023; 18(6):e0280586. PubMed ID: 37307267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes.
    Khang AR; Song YS; Kim KM; Moon JH; Lim S; Park KS; Jang HC; Choi SH
    J Clin Lipidol; 2016; 10(3):528-537.e3. PubMed ID: 27206940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence.
    Lee J; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS; Kim JH
    J Clin Pharm Ther; 2021 Feb; 46(1):134-142. PubMed ID: 33026659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Moderate-Intensity Statins for Low-Density Lipoprotein Cholesterol Level above 190 mg/dL at Baseline in Koreans.
    Kim HS; Lee H; Lee SH; Jeong YJ; Kim TM; Yang SJ; Baik SJ; Kim H; Lee SH; Cho JH; Choi IY; Yoon KH; Kim JH
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):272-278. PubMed ID: 28165667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
    Yu M; Liang C; Kong Q; Wang Y; Li M
    Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
    Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
    Sakuma M; Toyoda S; Hashimoto R; Yazawa H; Masuyama T; Hirose S; Waku R; Hasumi H; Numao T; Abe S; Inoue T
    Hypertens Res; 2019 Dec; 42(12):1923-1931. PubMed ID: 31409915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
    Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).
    Maron DJ; Hartigan PM; Neff DR; Weintraub WS; Boden WE;
    Am J Cardiol; 2013 Jun; 111(11):1557-62. PubMed ID: 23538020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A
    Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
    Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
    Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
    Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
    Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
    Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins.
    Fox KM; Tai MH; Kostev K; Hatz M; Qian Y; Laufs U
    Clin Res Cardiol; 2018 May; 107(5):380-388. PubMed ID: 29273856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.